Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 70.48 USD 0.14% Market Closed
Market Cap: 41.6B USD
Have any thoughts about
Edwards Lifesciences Corp?
Write Note

Edwards Lifesciences Corp
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Edwards Lifesciences Corp
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Edwards Lifesciences Corp
NYSE:EW
Net Change in Cash
$2.3B
CAGR 3-Years
67%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Net Change in Cash
$375m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Net Change in Cash
$1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Stryker Corp
NYSE:SYK
Net Change in Cash
$2B
CAGR 3-Years
N/A
CAGR 5-Years
131%
CAGR 10-Years
23%
Abbott Laboratories
NYSE:ABT
Net Change in Cash
-$848m
CAGR 3-Years
N/A
CAGR 5-Years
24%
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Net Change in Cash
-$1.2B
CAGR 3-Years
-267%
CAGR 5-Years
-98%
CAGR 10-Years
-29%
No Stocks Found

Edwards Lifesciences Corp
Glance View

Market Cap
41.6B USD
Industry
Health Care

Edwards Lifesciences Corp., a leader in heart valve technologies and hemodynamic monitoring, has carved out a vital niche in the medical device industry. Founded in 1958 and based in Irvine, California, the company has consistently focused on innovative solutions to treat advanced cardiovascular diseases. Its flagship product, the transcatheter aortic valve replacement (TAVR), revolutionized how patients with severe aortic stenosis are treated, allowing doctors to perform minimally invasive procedures that significantly improve patient outcomes. As the global population ages and cardiovascular diseases become increasingly prevalent, Edwards is well-positioned to capitalize on this growing demand, with a robust pipeline of products aimed at addressing unmet medical needs. For investors, Edwards Lifesciences represents a compelling opportunity to tap into the expanding medical technology market. The company's strong financial performance, characterized by consistent revenue growth and impressive profit margins, highlights its effective execution and market leadership. Moreover, Edwards is committed to innovation, investing heavily in research and development, which not only fuels new product launches but also enhances its competitive edge. With a focus on long-term growth, expanding market presence, and a dedication to improving patient care, Edwards Lifesciences stands out as a promising investment for those looking to gain exposure to the dynamic healthcare sector.

EW Intrinsic Value
54.97 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Edwards Lifesciences Corp's Net Change in Cash?
Net Change in Cash
2.3B USD

Based on the financial report for Sep 30, 2024, Edwards Lifesciences Corp's Net Change in Cash amounts to 2.3B USD.

What is Edwards Lifesciences Corp's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
67%

Over the last year, the Net Change in Cash growth was 1 299%. The average annual Net Change in Cash growth rates for Edwards Lifesciences Corp have been 67% over the past three years .

Back to Top